The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target

Background. c-MET is a receptor tyrosine kinase receptor (RTK) for the hepatocyte growth factor (HGF). The binding of HGF to c-MET regulates several cellular functions: differentiation, proliferation, epithelial cell motility, angiogenesis, and epithelial-mesenchymal transition (EMT). Moreover, it i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology 2022-01, Vol.2022, p.5179182-12
Main Authors: Faiella, Antonio, Riccardi, Ferdinando, Cartenì, Giacomo, Chiurazzi, Martina, Onofrio, Livia
Format: Article
Language:English
Subjects:
Angiogenesis
Binding sites
Carcinogenesis
Cell cycle
Cell differentiation
Development and progression
Growth factors
Health aspects
Immunoglobulins
Kinases
Ligands
Lung cancer
Metastasis
Monoclonal antibodies
Motility
Neutrophils
Phosphatase
Phosphorylation
Prognosis
Proteins
Review
Stem cells
Tumors
Tyrosine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. c-MET is a receptor tyrosine kinase receptor (RTK) for the hepatocyte growth factor (HGF). The binding of HGF to c-MET regulates several cellular functions: differentiation, proliferation, epithelial cell motility, angiogenesis, and epithelial-mesenchymal transition (EMT). Moreover, it is known to be involved in carcinogenesis. Comprehension of HGF-c-MET signaling pathway might have important clinical consequences allowing to predict prognosis, response to treatment, and survival rates based on its expression and dysregulation. Discussion. c-MET represents a useful molecular target for novel engineered drugs. Several clinical trials are underway for various solid tumors and the development of new specific monoclonal antibodies depends on the recent knowledge about the definite c-MET role in each different malignance. Recent clinical trials based on c-MET molecular targets result in good safety profile and represent a promising therapeutic strategy for solid cancers, in monotherapy or in combination with other target drugs. Conclusion. The list of cell surface receptors crosslinking with the c-MET signaling is constantly growing, highlighting the importance of this pathway for personalized target therapy. Research on the combination of c-MET inhibitors with other drugs will hopefully lead to discovery of new effective treatment options.
ISSN:1687-8450
1687-8450
1687-8469
DOI:10.1155/2022/5179182